Manufacturing Samsung Biologics inks $262M manufacturing deal with European pharma company BioSpaceThe agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea.Read full story pharminent September 11, 2026 (Last updated: September 16, 2026) BioSpace The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea. Read full story Post navigation Previous: Exegenesis Bio and Modalis sign research deal for Duchenne therapyNext: FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026